Results 31 to 40 of about 675,123 (288)

E-cadherin expression is associated with somatostatin analogue response in acromegaly [PDF]

, 2018
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
Cano, David A., Castaño, Justo P., Dios, Elena, Flores Martínez, Álvaro, Ibáñez Costa, Alejandro, Japón Rodríguez, Miguel Ángel, Luque, Raúl M., Madrazo Atutxa, Ainara, Soto Moreno, Alfonso Manuel, Venegas Moreno, Eva, Vázquez Borrego, Mari C.   +10 more
core   +1 more source

Resistance to Somatostatin Analogs in Acromegaly [PDF]

Endocrine Reviews, 2010
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia.
Colao, Annamaria, Auriemma, Renata S., Lombardi, Gaetano, Pivonello, Rosario   +3 more
openaire   +4 more sources

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +6 more sources

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Clinical Medicine Insights: Cardiology, 2020
Neuroendocrine tumors (NETs, originally termed “carcinoids”) create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons.
Barbara Bober, Marek Saracyn, Maciej Kołodziej, Łukasz Kowalski, Elżbieta Deptuła-Krawczyk, Waldemar Kapusta, Grzegorz Kamiński, Olga Mozenska, Jacek Bil   +8 more
doaj   +1 more source

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

Journal of the Formosan Medical Association, 2016
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.
Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chang   +2 more
doaj   +1 more source

Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?

Genel Tıp Dergisi, 2022
Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor ...
Çağlagül Erol, Ahmet Volkan Çelik, Özlem Şahin, Gonca Kara Gedik, Hasan Önner, Farise Yılmaz   +5 more
doaj   +1 more source

Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors [PDF]

, 1997
The effects of somatostatin (SS-14 and/or SS-28) and of the three octapeptide SS-analogs that are available for clinical use (octreotide, BIM-23014 and RC-160) on hormone release by primary cultures of 15 clinically ...
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Koetsveld, P.M. (Peter) van, Kros, J.M. (Johan), Lamberts, S.W.J. (Steven), Uffelen, C. van, Uitterlinden, P. (Piet), Visser-Wisselaar, H.A. (Heleen), Waaijers, M. (Marlijn), Zuyderwijk, J.   +9 more
core   +3 more sources

Progress in the formulation and delivery of somatostatin analogs for acromegaly.

Therapeutic delivery, 2017
A 14 amino acid cystin bridge containing neuropeptide was discovered in 1973 and designated as growth hormone-inhibiting hormone, in other words, somatostatin.
Sarinj Fattah, David J Brayden
semanticscholar   +1 more source